JP5750444B2 - 角膜内皮障害治療剤（ｙ−３９９８３） - Google Patents

角膜内皮障害治療剤（ｙ−３９９８３） Download PDF

Info

Publication number
JP5750444B2
JP5750444B2 JP2012530000A JP2012530000A JP5750444B2 JP 5750444 B2 JP5750444 B2 JP 5750444B2 JP 2012530000 A JP2012530000 A JP 2012530000A JP 2012530000 A JP2012530000 A JP 2012530000A JP 5750444 B2 JP5750444 B2 JP 5750444B2
Authority
JP
Japan
Prior art keywords
corneal endothelial
compound
corneal
present
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012530000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515676A (ja
JP2013515676A5 (cg-RX-API-DMAC10.html
Inventor
浩昭 高橋
浩昭 高橋
坂本　雄二
雄二 坂本
徹郎 喜田
徹郎 喜田
毅 樽井
毅 樽井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Tanabe Pharma Corp
Original Assignee
Senju Pharmaceutical Co Ltd
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd, Mitsubishi Tanabe Pharma Corp filed Critical Senju Pharmaceutical Co Ltd
Priority to JP2012530000A priority Critical patent/JP5750444B2/ja
Publication of JP2013515676A publication Critical patent/JP2013515676A/ja
Publication of JP2013515676A5 publication Critical patent/JP2013515676A5/ja
Application granted granted Critical
Publication of JP5750444B2 publication Critical patent/JP5750444B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012530000A 2009-12-29 2010-12-28 角膜内皮障害治療剤（ｙ−３９９８３） Expired - Fee Related JP5750444B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012530000A JP5750444B2 (ja) 2009-12-29 2010-12-28 角膜内皮障害治療剤（ｙ−３９９８３）

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2009299180 2009-12-29
JP2009299180 2009-12-29
JPPCT/JP2010/071424 2010-11-24
PCT/JP2010/071424 WO2011080984A1 (en) 2009-12-29 2010-11-24 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
JP2012530000A JP5750444B2 (ja) 2009-12-29 2010-12-28 角膜内皮障害治療剤（ｙ−３９９８３）
PCT/JP2010/073904 WO2011081221A1 (en) 2009-12-29 2010-12-28 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015100969A Division JP2015155460A (ja) 2009-12-29 2015-05-18 角膜内皮障害治療剤（ｙ−３９９８３）

Publications (3)

Publication Number Publication Date
JP2013515676A JP2013515676A (ja) 2013-05-09
JP2013515676A5 JP2013515676A5 (cg-RX-API-DMAC10.html) 2014-02-13
JP5750444B2 true JP5750444B2 (ja) 2015-07-22

Family

ID=43598277

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012530000A Expired - Fee Related JP5750444B2 (ja) 2009-12-29 2010-12-28 角膜内皮障害治療剤（ｙ−３９９８３）
JP2015100969A Pending JP2015155460A (ja) 2009-12-29 2015-05-18 角膜内皮障害治療剤（ｙ−３９９８３）

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015100969A Pending JP2015155460A (ja) 2009-12-29 2015-05-18 角膜内皮障害治療剤（ｙ−３９９８３）

Country Status (10)

Country Link
US (1) US20120288482A1 (cg-RX-API-DMAC10.html)
EP (1) EP2519237A1 (cg-RX-API-DMAC10.html)
JP (2) JP5750444B2 (cg-RX-API-DMAC10.html)
KR (1) KR20120099147A (cg-RX-API-DMAC10.html)
CN (1) CN102770136A (cg-RX-API-DMAC10.html)
BR (1) BR112012016128A8 (cg-RX-API-DMAC10.html)
CA (1) CA2785851A1 (cg-RX-API-DMAC10.html)
MX (1) MX2012007671A (cg-RX-API-DMAC10.html)
RU (1) RU2563141C2 (cg-RX-API-DMAC10.html)
WO (2) WO2011080984A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201903889T4 (tr) * 2011-12-06 2019-04-22 Astellas Inst For Regenerative Medicine Korneal endotelyal hücreler üreten yönlendirilmiş diferansiyasyona yönelik yöntem.
BR112016011096A2 (pt) 2013-11-27 2017-09-19 Kyoto Prefectural Public Univ Corp Aplicação de laminina à cultura de célula endotelial da córnea
US10959997B2 (en) 2013-12-27 2021-03-30 Kyoto Prefectural Public University Corporation Combined agent for cell therapy of corneal endothelial cell
CN106604730B (zh) * 2014-09-24 2019-12-20 兴和株式会社 角膜厚度调节剂
MX387839B (es) * 2014-10-31 2025-03-04 Senju Pharma Co Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea.
JP6770435B2 (ja) 2014-10-31 2020-10-14 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
EP3416658B1 (en) * 2016-02-15 2023-03-22 Kyoto Prefectural Public University Corporation Human functional corneal endothelial cell and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
CA2443918C (en) 2001-04-11 2012-06-05 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents containing rho kinase inhibitors
JP2004024852A (ja) 2002-04-30 2004-01-29 Amniotec:Kk 角膜内皮様シート、及びその作製方法
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EP1752456B1 (en) * 2004-06-03 2015-08-26 Senju Pharmaceutical Co., Ltd. Corneal perception recovery drug containing amide compound
WO2006057270A1 (ja) * 2004-11-26 2006-06-01 Asahi Kasei Pharma Corporation 含窒素３環化合物
JP4766653B2 (ja) * 2005-01-28 2011-09-07 株式会社林原生物化学研究所 眼科用医薬組成物
WO2006095844A1 (ja) * 2005-03-10 2006-09-14 Mitsubishi Pharma Corporation 医薬製剤
WO2007083685A1 (ja) * 2006-01-19 2007-07-26 Senju Pharmaceutical Co., Ltd. 生体内で細胞増殖可能な角膜内皮製剤
WO2008016016A1 (fr) * 2006-07-31 2008-02-07 Senju Pharmaceutical Co., Ltd. Préparation liquide aqueuse contenant un amide
KR20240045364A (ko) 2007-08-29 2024-04-05 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
JP5251632B2 (ja) 2008-05-13 2013-07-31 新日鐵住金株式会社 耐遅れ破壊特性に優れた高強度鋼材、高強度ボルト及びその製造方法
JP2010071424A (ja) 2008-09-19 2010-04-02 Toyota Motor Corp 変速機の制御装置

Also Published As

Publication number Publication date
RU2563141C2 (ru) 2015-09-20
JP2013515676A (ja) 2013-05-09
MX2012007671A (es) 2012-08-23
EP2519237A1 (en) 2012-11-07
BR112012016128A2 (pt) 2016-05-31
WO2011080984A1 (en) 2011-07-07
BR112012016128A8 (pt) 2017-12-05
CA2785851A1 (en) 2011-07-07
JP2015155460A (ja) 2015-08-27
US20120288482A1 (en) 2012-11-15
KR20120099147A (ko) 2012-09-06
RU2012132443A (ru) 2014-02-10
CN102770136A (zh) 2012-11-07
WO2011081221A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
JP7631270B2 (ja) 角膜内皮細胞接着促進剤
JP2015155460A (ja) 角膜内皮障害治療剤（ｙ−３９９８３）
EP3733177B1 (en) Composition for protecting cornea
US11857544B2 (en) Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases
US20230142705A1 (en) Use of anti-aging glycopeptides for inhibition of immune rejection of a graft
HK40038538A (en) Composition for protecting cornea
HK40038538B (en) Composition for protecting cornea

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140902

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20140902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140902

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150518

R150 Certificate of patent or registration of utility model

Ref document number: 5750444

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees